Table 2.
Hazard ratios (HRs) and 95% confidence intervals (CIs) reported in trials on adjvuant chemotherapy in grade II and III glioma
| Histology | Trial Question | n | Median OS, y | HR [95% CI] for OS |
|---|---|---|---|---|
| Anaplastic oligodendroglioma98 | RT/PCV vs RT | 368 | 3.5 vs 2.5 | 0.75 [0.60, 0.95] |
| Anaplastic oligodendroglioma97 | RT/PCV-i vs RT | 291 | 4.6 vs 4.7 | 0.79 [0.60, 1.04] |
| Low-grade glioma81 | RT/PCV vs RT | 251 | 13.3 vs 7.8 | 0.59 [0.42, 0.83] |
| Anaplastic astrocytoma110 | RT/carmustine + DBD vs RT | 193 | 2.3 vs 2.0 | 0.77 [0.56, 1.06] |
| Anaplastic glioma, 1p/19q intact99 | RT/TMZ vs RT | 745 | NR vs 3.4 | 0.65* (0.45, 0.93 |
| Anaplastic glioma102 | TMZ or PCV vs RT | 318 | 6.9 vs 6.0 | 1.11 [0.8, 1.55] |
| Low-grade glioma103 | RT vs TMZ | 447 | 3.3 vs 3.8 (PFS) | 1.16 [0.9, 1.5] |
| Anaplastic astrocytoma111 | RT/TMZ vs RT/lomustine or carmustine | 197 | 3.9 vs 3.8 | 0.94 [0.67, 1.32] |
*99.145 % confidence interval; °Primary endpoint: PFS; DBD: dibromodulciterol; RT: radiotherapy; NR: not reached.
Adapted with permission from: Martin J. van den Bent, Susan M. Chang. “Grade II and III Oligodendroglioma and Astrocytoma”, Neurologic Clinics, 2018, Elsevier.